Andrew Whelton

Summary

Publications

  1. doi request reprint Renal function in gout: long-term treatment effects of febuxostat
    Andrew Whelton
    Universal Clinical Research Center, Inc, 1737 Beaver Brook Lane, Hunt Valley, MD 21030 1603, USA
    J Clin Rheumatol 17:7-13. 2011
  2. ncbi request reprint Renal and related cardiovascular effects of conventional and COX-2-specific NSAIDs and non-NSAID analgesics
    A Whelton
    Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
    Am J Ther 7:63-74. 2000
  3. ncbi request reprint Cardiorenal effects of celecoxib as compared with the nonsteroidal anti-inflammatory drugs diclofenac and ibuprofen
    A Whelton
    The Universal Clinical Research Center Inc, Hunt Valley, Maryland 21030 1603, USA
    Kidney Int 70:1495-502. 2006
  4. doi request reprint Preservation of renal function during gout treatment with febuxostat: a quantitative study
    Andrew Whelton
    Universal Clinical Research Center, Inc, Hunt Valley, MD, USA
    Postgrad Med 125:106-14. 2013
  5. doi request reprint Current and future therapeutic options for the management of gout
    Andrew Whelton
    Universal Clinical Research Center, Inc, Hunt Valley, MD, USA
    Am J Ther 17:402-17. 2010
  6. ncbi request reprint Clinical implications of nonopioid analgesia for relief of mild-to-moderate pain in patients with or at risk for cardiovascular disease
    Andrew Whelton
    The Universal Clinical Research Center, Inc, Hunt Valley, Maryland, USA
    Am J Cardiol 97:3-9. 2006
  7. ncbi request reprint Effects of celecoxib and naproxen on renal function in the elderly
    A Whelton
    Universal Clinical Research Center, Inc, Hunt Valley, MD 21030 1603, USA
    Arch Intern Med 160:1465-70. 2000
  8. ncbi request reprint COX-2-specific inhibitors and the kidney: effect on hypertension and oedema
    Andrew Whelton
    Universal Clinical Research Center, Inc, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
    J Hypertens Suppl 20:S31-5. 2002
  9. ncbi request reprint Effects of celecoxib and rofecoxib on blood pressure and edema in patients > or =65 years of age with systemic hypertension and osteoarthritis
    Andrew Whelton
    Universal Clinical Research Center, Inc, and The Johns Hopkins University School of Medicine, Baltimore, Maryland 21030 1603, USA
    Am J Cardiol 90:959-63. 2002
  10. ncbi request reprint Effects of the cyclooxygenase-2 specific inhibitor valdecoxib versus nonsteroidal antiinflammatory agents and placebo on cardiovascular thrombotic events in patients with arthritis
    William B White
    Division of Hypertension and Clinical Pharmacology, Department of Medicine, University of Connecticut School of Medicine, 263 Farmington Avenue, Farmington, CT 06030 3940, USA
    Am J Ther 11:244-50. 2004

Detail Information

Publications23

  1. doi request reprint Renal function in gout: long-term treatment effects of febuxostat
    Andrew Whelton
    Universal Clinical Research Center, Inc, 1737 Beaver Brook Lane, Hunt Valley, MD 21030 1603, USA
    J Clin Rheumatol 17:7-13. 2011
    ..In healthy adults, glomerular filtration rate wanes with age. Urate-lowering therapy (ULT) with allopurinol has been shown to stabilize or reverse this...
  2. ncbi request reprint Renal and related cardiovascular effects of conventional and COX-2-specific NSAIDs and non-NSAID analgesics
    A Whelton
    Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
    Am J Ther 7:63-74. 2000
    ..It is important that healthcare providers and practitioners are aware of the relative renal risks of different analgesics and that they use this knowledge to counsel the analgesic-consuming population appropriately...
  3. ncbi request reprint Cardiorenal effects of celecoxib as compared with the nonsteroidal anti-inflammatory drugs diclofenac and ibuprofen
    A Whelton
    The Universal Clinical Research Center Inc, Hunt Valley, Maryland 21030 1603, USA
    Kidney Int 70:1495-502. 2006
    ..3%; P < 0.05) and ibuprofen (7.3%; P < 0.05). A supratherapeutic dose of celecoxib was associated with an improved cardiorenal safety profile compared with standard doses of either ibuprofen or diclofenac...
  4. doi request reprint Preservation of renal function during gout treatment with febuxostat: a quantitative study
    Andrew Whelton
    Universal Clinical Research Center, Inc, Hunt Valley, MD, USA
    Postgrad Med 125:106-14. 2013
    ..Hyperuricemia can accelerate renal decline associated with aging. Chronic kidney disease is frequently seen in patients with hyperuricemia and gout...
  5. doi request reprint Current and future therapeutic options for the management of gout
    Andrew Whelton
    Universal Clinical Research Center, Inc, Hunt Valley, MD, USA
    Am J Ther 17:402-17. 2010
    ..This manuscript reviews the pathophysiology of hyperuricemia and gout, and associated comorbidities, and then discusses traditional therapeutic options, newly available agents, and future targets for pharmacologic management...
  6. ncbi request reprint Clinical implications of nonopioid analgesia for relief of mild-to-moderate pain in patients with or at risk for cardiovascular disease
    Andrew Whelton
    The Universal Clinical Research Center, Inc, Hunt Valley, Maryland, USA
    Am J Cardiol 97:3-9. 2006
    ....
  7. ncbi request reprint Effects of celecoxib and naproxen on renal function in the elderly
    A Whelton
    Universal Clinical Research Center, Inc, Hunt Valley, MD 21030 1603, USA
    Arch Intern Med 160:1465-70. 2000
    ..To compare the effects of celecoxib, a cyclooxygenase 2-specific inhibitor, with the nonspecific cyclooxygenase 1 and 2 inhibitor naproxen on renal function in 29 healthy elderly subjects in a single-blind, randomized, crossover study...
  8. ncbi request reprint COX-2-specific inhibitors and the kidney: effect on hypertension and oedema
    Andrew Whelton
    Universal Clinical Research Center, Inc, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
    J Hypertens Suppl 20:S31-5. 2002
    ..4% compared with 0.1% in the naproxen group, P < 0.05). In summary, celecoxib may have safety and tolerability advantages compared with non-selective NSAIDs studied and may have some cardiorenal benefits compared with rofecoxib...
  9. ncbi request reprint Effects of celecoxib and rofecoxib on blood pressure and edema in patients > or =65 years of age with systemic hypertension and osteoarthritis
    Andrew Whelton
    Universal Clinical Research Center, Inc, and The Johns Hopkins University School of Medicine, Baltimore, Maryland 21030 1603, USA
    Am J Cardiol 90:959-63. 2002
    ..7%) compared with the celecoxib group (4.7%) (p <0.05). Thus, in patients with controlled hypertension on a fixed antihypertensive regimen, careful monitoring of BP is warranted after the initiation of celecoxib or rofecoxib therapy...
  10. ncbi request reprint Effects of the cyclooxygenase-2 specific inhibitor valdecoxib versus nonsteroidal antiinflammatory agents and placebo on cardiovascular thrombotic events in patients with arthritis
    William B White
    Division of Hypertension and Clinical Pharmacology, Department of Medicine, University of Connecticut School of Medicine, 263 Farmington Avenue, Farmington, CT 06030 3940, USA
    Am J Ther 11:244-50. 2004
    ....
  11. doi request reprint Minimizing cardiovascular complications during the treatment of osteoarthritis
    Andrew Whelton
    Universal Clinical Research Center, Inc, Baltimore, MD, USA
    Am J Ther 18:466-76. 2011
    ....
  12. ncbi request reprint Effects of the selective cyclooxygenase-2 inhibitor analgesic celecoxib on renal carbonic anhydrase enzyme activity: a randomized, controlled trial
    Arnold B Alper
    Department of Medicine, Tulane University Health Sciences Center, New Orleans, LA 70112, USA
    Am J Ther 13:229-35. 2006
    ..Thus, in this short-term study of human subjects, therapeutic doses of celecoxib did not appear to have a clinically significant inhibitory action on renal carbonic anhydrase...
  13. ncbi request reprint The coxib conundrum: lessons from the rise and fall of rofecoxib
    Andrew Whelton
    Am J Ther 11:417-21. 2004
  14. ncbi request reprint Blood pressure destabilization and related healthcare utilization among hypertensive patients using nonspecific NSAIDs and COX-2-specific inhibitors
    Sean Z Zhao
    Pharmacia Corporation, Peapack, New Jersey, USA
    Am J Manag Care 8:S401-13. 2002
    ....
  15. ncbi request reprint Cost of heart failure among hypertensive users of nonspecific NSAIDs and COX-2-specific inhibitors
    Sean Z Zhao
    Pharmacia Corporation, Peapack, New Jersey, USA
    Am J Manag Care 8:S414-27. 2002
    ..To determine the costs of heart failure in hypertensive patients receiving celecoxib, rofecoxib, and nonspecific nonsteroidal anti-inflammatory drugs (NSAIDs) in clinical practice...
  16. ncbi request reprint Comparison of thromboembolic events in patients treated with celecoxib, a cyclooxygenase-2 specific inhibitor, versus ibuprofen or diclofenac
    William B White
    Section of Hypertension and Clinical Pharmacology, University of Connecticut School of Medicine, Farmington, Connecticut 06030 3940, USA
    Am J Cardiol 89:425-30. 2002
    ....
  17. pmc Cognitive function over time in the Alzheimer's Disease Anti-inflammatory Prevention Trial (ADAPT): results of a randomized, controlled trial of naproxen and celecoxib
    Barbara K Martin
    Arch Neurol 65:896-905. 2008
    ..Observational studies have shown reduced risk of Alzheimer dementia in users of nonsteroidal anti-inflammatory drugs...
  18. ncbi request reprint Thromboembolic cardiovascular risk among arthritis patients using cyclooxygenase-2-selective inhibitor or nonselective cyclooxygenase inhibitor nonsteroidal anti-inflammatory drugs
    William M Spalding
    Pfizer Inc, New York, NY, USA
    Am J Ther 14:3-12. 2007
    ..That this effect was specific to hypertensive patients indicates that blood pressure destabilization is likely an important contributing mechanism...
  19. ncbi request reprint Effects of celecoxib on ambulatory blood pressure in hypertensive patients on ACE inhibitors
    William B White
    Section of Hypertension and Clinical Pharmacology, University of Connecticut School of Medicine, Farmington, CT 06030 3940, USA
    Hypertension 39:929-34. 2002
    ..The placebo-subtracted changes observed in 24-hour BP (1.6/1.2 mm Hg) are less than what has been reported for nonselective nonsteroidal anti-inflammatory agents in ACE inhibitor-treated patients...
  20. ncbi request reprint Controversies in COX-2 selective inhibition
    Lee S Simon
    Beth Israel Deaconess Medical Center, Boston, MA 02215, USA
    J Rheumatol 29:1501-10. 2002
  21. ncbi request reprint Physician-reported management of edema and destabilized blood pressure in cyclooxygenase-2-specific inhibitor users with osteoarthritis and treated hypertension
    Jane T Osterhaus
    Wasatch Health Outcomes, Park City, Utah 84060, USA
    Clin Ther 24:969-89. 2002
    ..The addition of a nonsteroidal anti-inflammatory drug to the regimen of a patient with treated hypertension can cause a destabilization of blood pressure...
  22. ncbi request reprint The Effects of cyclooxygenase-2 inhibitors and nonsteroidal anti-inflammatory therapy on 24-hour blood pressure in patients with hypertension, osteoarthritis, and type 2 diabetes mellitus
    James R Sowers
    State University of New York, Brooklyn, USA
    Arch Intern Med 165:161-8. 2005
    ..Therefore, we conducted a double-blind, randomized trial to evaluate the effects of celecoxib, rofecoxib, and naproxen on 24-hour blood pressure (BP) in patients with type 2 diabetes, hypertension, and osteoarthritis...
  23. ncbi request reprint Comparison of the baseline cardiovascular risk profile among hypertensive patients prescribed COX-2-specific inhibitors or nonspecific NSAIDs: data from real-life practice
    Sean Z Zhao
    Pharmacia Corporation, Peapack, New Jersey, USA
    Am J Manag Care 8:S392-400. 2002
    ..To evaluate the baseline cardiovascular (CV) risk of hypertensive patients newly starting cyclooxygenase (COX)-2-specific inhibitors (celecoxib or rofecoxib) or nonspecific nonsteroidal anti-inflammatory drugs (NSAIDs)...